A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants

A Phase 1, Open-label, Randomized, Single-dose, 3-Period, 3-Sequence Crossover Study to Assess the Relative Bioavailability of the Intended Commercial Formulation Versus the Previous MyoKardia Formulation of Danicamtiv and to Assess the Effect of Food on the Pharmacokinetics of the Intended Commercial Formulation in Healthy Adult Participants

The purpose of this study is to assess the relative biological availability and the effect of food on the drug levels of Danicamtiv in health adults.

Inclusion Criteria:

• Body mass index (BMI) of 18.0 kg/m2 to 30.0 kg/m2 inclusive
• Participants with resting heart rate ≥ 55 bpm
• Seasonal allergies that do not require medication at the time of the study are acceptable

Exclusion Criteria:

• Any acute or chronic medical illness
• Head injury, intracranial tumor, or aneurysm within 2 years prior to screening
• History of chronic gastrointestinal disorders or gastrointestinal (GI) surgery (including cholecystectomy) that could impact on drug and food absorption and/or drug excretion